An idea on the interference between oxaliplatin and anti-EGFR therapies
What is it about?
When oxaliplatin has been combined with anti-EGFR therapies, a detrimental effect has been observed in KRAS mutated patients. Even for wild-type patients, anti-EGFRs seem not to be the best partner for oxaliplatin. In this paper we describe our hypothesis concerning this supposed negative interference.
Why is it important?
This paper, with an original point of view, gives reason both of detrimental effect observed in KRAS mutated and also of the puzzling results observed when oxaliplatin has been combined with anti-EGFR therapies even in wild type RAS patients. Moreover our point of view seems to be able to explain some particular issues, such as the detrimental effect observed in the microscopic disease of wild-type patients.
The following have contributed to this page: Michele Basso
In partnership with: